New Mutations in Topoisomerase I Linked to Drug Resistance
Author Information
Author(s): Céline Gongora, Nadia Vezzio-Vie, Sandie Tuduri, Vincent Denis, Annick Causse, Céline Auzanneau, Gwenaëlle Collod-Beroud, Arnaud Coquelle, Philippe Pasero, Philippe Pourquier, Pierre Martineau, Maguy Del Rio
Primary Institution: IRCM, Institut de Recherche en Cancérologie de Montpellier
Hypothesis
Are mutations in Topoisomerase I associated with resistance to the drug SN38?
Conclusion
The study found that specific mutations in Topoisomerase I contribute to the development of resistance to SN38 in colon cancer cells.
Supporting Evidence
- Three new mutations in Topoisomerase I were identified in resistant cell lines.
- Mutations did not change the expression or intrinsic activity of Topoisomerase I.
- Resistance was associated with reduced formation of DNA cleavage complexes.
Takeaway
Some changes in a protein called Topoisomerase I can make cancer cells resistant to a medicine that usually helps treat them.
Methodology
The study involved creating resistant cell lines and analyzing mutations in Topoisomerase I, along with assessing drug sensitivity and DNA damage.
Limitations
The mutations were not detected in clinical samples from patients, suggesting they may be rare or present in low frequencies.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website